vatalanib

Phase 2Completed
0 watching 0 views this week Active
52
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Brain and Central Nervous System Tumors

Conditions

Brain and Central Nervous System Tumors, Sarcoma

Trial Timeline

May 1, 2006 → Jul 1, 2013

About vatalanib

vatalanib is a phase 2 stage product being developed by Novartis for Brain and Central Nervous System Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT00348790. Target conditions include Brain and Central Nervous System Tumors, Sarcoma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (4)

NCT IDPhaseStatus
NCT00348790Phase 2Completed
NCT00590343Phase 2Completed
NCT00056459Phase 3Completed
NCT00056446Phase 3Completed

Competing Products

20 competing products in Brain and Central Nervous System Tumors

See all competitors
ProductCompanyStageHype Score
Abemaciclib + Endocrine therapyEli LillyPhase 1/2
41
Duloxetine + Sugar pillEli LillyPhase 2
52
Neurosteroid enantiomerOragenicsPhase 2
44
Patritumab deruxtecanDaiichi SankyoPhase 2
52
filgrastim + exatecan mesylateDaiichi SankyoPhase 1
33
Eribulin MesylateEisaiPhase 1
33
Pembrolizumab + LenvatinibEisaiPhase 2
52
Palonosetron (Aloxi) and DexamethasoneEisaiPhase 2
52
GLIADELEisaiPhase 2
52
Nivolumab + TemozolomideOno PharmaceuticalPhase 3
77
Nivolumab + TemozolomideOno PharmaceuticalPhase 3
77
Prexasertib + Cyclophosphamide + Gemcitabine + filgrastim + peg-filgrastimEli LillyPhase 1
33
abemaciclib + abemaciclibEli LillyPhase 2
52
JNJ-17299425Johnson & JohnsonPhase 2
52
ABT-888AbbViePhase 1
33
Veliparib + PlaceboAbbViePhase 2
52
Iressa (Gefitinib)AstraZenecaPhase 2
52
Trastuzumab deruxtecanAstraZenecaPhase 2
52
ExenatideAstraZenecaApproved
85
AZD5213AstraZenecaPhase 1
33